Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Posts Earnings Results

Posted by Brenda Bartman on May 14th, 2026

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $1.08 earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $834.86 million for the quarter. Recordati Industria Chimica E Farmaceutica had a net margin of 16.92% and a return on equity of 34.11%.

Recordati Industria Chimica E Farmaceutica Price Performance

RCDTF stock remained flat at $55.88 during midday trading on Thursday. The company has a market capitalization of $11.53 billion, a PE ratio of 23.35 and a beta of 0.23. The stock’s fifty day simple moving average is $56.71 and its 200 day simple moving average is $62.13. Recordati Industria Chimica E Farmaceutica has a one year low of $55.88 and a one year high of $56.95. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.16 and a current ratio of 1.64.

Analyst Ratings Changes

Several research firms have recently weighed in on RCDTF. Barclays raised shares of Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 12th. Kepler Capital Markets raised Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Recordati Industria Chimica E Farmaceutica presently has a consensus rating of “Buy”.

Check Out Our Latest Analysis on Recordati Industria Chimica E Farmaceutica

About Recordati Industria Chimica E Farmaceutica

(Get Free Report)

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.